Format

Send to

Choose Destination
Future Microbiol. 2019 Sep;14:1083-1085. doi: 10.2217/fmb-2019-0210.

Is Candida auris here to stay? An interview with Dimitrios Kontoyiannis.

Author information

1
Division of Internal Medicine the University of Texas, MD Anderson Cancer Center, ECMM Diamond Excellence in Mycology Center/www.ecmm.info, 1400 Pressler Street, FCT 12.5069, Unit 1463, Houston, TX 77030-3772, USA.

Abstract

In this exclusive interview, Dimitrios P Kontoyiannis discusses current mycology hot topic, Candida auris. With a focus on the current knowns and unknowns for the pathogenesis, resistance and transmission of this emerging fungal pathogen, in addition to a look at therapeutics and future perspectives. This interview was conducted by Ellen Colvin, Commissioning Editor of Future Microbiology. Dimitrios P Kontoyiannis is the Texas 4000 distinguished endowed professor and deputy head in the Division of Internal Medicine at MD Anderson Cancer Center in Houston (TX, USA). Dr Kontoyiannis has authored over 550 peer-reviewed manuscripts and has given over 330 lectures in national and international conferences and academic institutions in the USA and abroad. He is considered a leading mycology expert world-wide with an H index of 101 and over 43,000 citations. His research group is credited for many and sustained contributions to clinical, translational and experimental mycology. He is the recipient of many national and international awards and is the past president elect of Immunocompromised Host Society (2016-2018).

KEYWORDS:

Candida auris; MALDI-TOF mass spectrometry; PCR; amphotericin B; azoles; echinocandin; multidrug resistance; point-of-care testing; rezafungin

PMID:
31512518
DOI:
10.2217/fmb-2019-0210
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center